Earnings call transcript: InnovAge tops fiscal 2026 with profit surge, shares jump after hours

InnovAge fiscal 2026 revenue rose 15.9% to $989.7 million and adjusted EBITDA surged 175% to $94.6 million, lifting EBITDA margin 270bps to 9.6%; its net loss narrowed to $0.7 million from $35.3 million. The company guided fiscal 2027 revenue to $1.05-$1.085 billion and adjusted EBITDA to $105-$115 million, implying a 10.0%-10.6% margin, supported by census growth, utilization management and operating efficiencies. Shares rose 9.03% after hours to $11.47, though uncertainty remains around California and Colorado reimbursement rates, which affect about 70% of census.

Analysis

INNV’s re-rating hinges less on the headline EBITDA step-up than on whether center-level economics remain intact as favorable reimbursement true-ups roll off. The FY27 midpoint implies roughly 70 bps of further EBITDA-margin expansion despite a much weaker rate tailwind; this makes utilization management, enrollment retention, and labor/transport productivity the critical quarterly KPIs. The concentrated exposure to two yet-unresolved state rate processes creates a binary catalyst within the next 1-3 months: even a modest adverse rate variance can erase the guided margin expansion because much of the cost base is fixed over a plan year.

The important structural change is that mature centers are exiting their loss-ramp period, reducing the drag on consolidated earnings and improving free-cash conversion without requiring materially faster enrollment. That supports a 6-18 month acquisition optionality thesis: scaled operators with compliant infrastructure should have an advantage acquiring smaller PACE assets that cannot absorb technology, quality, and administrative requirements. However, prior compliance history means growth through M&A or relaxed enrollment rules would likely increase—not reduce—regulatory scrutiny; the market should not capitalize exploratory federal policy dialogue until a formal CMS/CMMI model or rulemaking appears.

Consensus may underappreciate the valuation risk of a narrow 10% margin endpoint. Once INNV is valued as a stable value-based-care platform, the stock becomes sensitive to any evidence that savings are merely deferred care or that medical-cost controls impair quality measures, referrals, or retention. AI claims are immaterial to FY27 valuation until management discloses hard outcomes—avoidable admissions, specialist-referral rates, transportation cost per trip, or care-team productivity—rather than pilots. CRM and ORCL are implementation vendors, not clean earnings beneficiaries; INNV’s modest scale is unlikely to move either company’s estimates.

Key Decisions for Investors

• Tactical long INNV only on confirmation that California and Colorado rate outcomes support the current guide; target a 15-25% rerating over 3-6 months if EBITDA guidance is maintained through the first two reported quarters. Exit or hedge if either state outcome forces a FY27 EBITDA-guide cut, or if center contribution margin falls below ~22.5% for two consecutive quarters.
• For existing INNV exposure, take partial profits into a move near the prior high and retain a smaller core position for M&A/policy optionality. The asymmetric near-term risk is that the market prices the upper end of guidance before state rates and medical-cost trends are independently validated.
• Monitor quarterly member-month growth versus the 5-7.5% ending-census framework and external provider cost per participant. A combination of sub-5% census growth and rising external-care costs would invalidate the operating-leverage thesis even if reported revenue remains supported by reimbursement.
• Do not initiate a CRM or ORCL read-through trade from the stated technology standardization. Create an alert only if INNV provides contract scale, implementation spend, or measurable productivity data indicating broader PACE adoption; current customer-level exposure is too small to affect vendor earnings.